{"id":1068279,"date":"2023-04-09T00:04:11","date_gmt":"2023-04-09T04:04:11","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"},"modified":"2024-08-18T11:45:16","modified_gmt":"2024-08-18T15:45:16","slug":"affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement.php","title":{"rendered":"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement"},"content":{"rendered":"<p><![CDATA[HEIDELBERG, Germany, April  06, 2023  (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the \u201cNotice\u201d), dated April 4, 2023, from the\u00a0Listing Qualifications Department\u00a0of The\u00a0Nasdaq Stock Market LLC\u00a0(\u201cNasdaq\u201d) indicating that, for the last thirty consecutive business days, the bid price for the Company\u2019s common shares had closed below the minimum\u00a0$1.00\u00a0per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Rule\u201d).]]><\/p>\n<p>More:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/04\/06\/2642980\/0\/en\/Affimed-Announces-Receipt-of-NASDAQ-Deficiency-Notice-Regarding-Minimum-Bid-Price-Requirement.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement\">Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>More: Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068279","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068279"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068279"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068279\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}